Kodak was a satiric example, but not comparing - simply saying someone else e.g. Lonza or other cell manufacturers will be awarded not MSB. Rem-L doesn't have a patent (only pending) for Covid-ards. So it's a blessing for the world after all - no one to pay for the licensing of a remedy, only manufacturing costs (which is why we raised through BP).
Unfortunately, Lonza are the established CSL in this instance and are 40 steps ahead, already building infrastructure in China / US / Europe to manufacture. They got the inside scoop. Would've been a different game if we were the sole manufacturers.
Still have Heart and back in the game, but pre-curser cells may not be as pluripotent.
MSB Trading 2020 - a new dawn, page-1571
-
- There are more pages in this discussion • 11,500 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |